NEOGENOMICS INC (NEO) research
NEOGENOMICS INC- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $19.91
- As of
NEOGENOMICS INC (NEO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for NEO. Method and limitations.
Share the NEO intelligence card
See NEO live in the terminal
Track NEO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live NEO terminal, freeActive signals for NEO
- highCONSENSUS_SELL
3 tracked funds reduced NEO this 2026Q2, institutional consensus
- highCONSENSUS_SELL
3 tracked funds reduced NEO this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 77% of NEO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 85% of NEO (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 77% of NEO (2026Q2)
FREE, NO ACCOUNT
Every signal on NEO, as it fires
You are seeing 5 of 25 signals recorded on NEO since 2026-05-31.
The five above landed across 2 days. The other 20 were recorded on 4 other days. 15 of the 25 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NEO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 64049M209 · 2026Q2 | $44.9M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 64049M209 · 2026Q2 | $32M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 64049MAB6 · 2026Q2 | $2.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 64049M209 · 2026Q2 | $576K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NEO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NEO mentioned in Kresmion daily briefs
NEO against its peers
NEO's operating margin of -15.9% ranks in the 50th percentile of 18 Diagnostics & Research sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | NEO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 727M USD | 77.2M USD | 88 | 19 |
| Gross margin | 43.2% | 63.2% | 19 | 12 |
| Operating margin | -15.9% | -16.4% | 50 | 18 |
| Net margin | -14.9% | -20.6% | 53 | 19 |
| Return on equity | -12.9% | -4.8% | 38 | 16 |
Peers (21): CDNA, PSNL, OPK, BLLN, QGEN, TWST, ICLR, BDSX, BNR, IMDX, FONR, QUCY, MDXH, PRPO, IDXG, LDDD, AWHL, MBAI, NDRA, XWEL, ISPC. Left out: ANPCF (no annual filing), PMDI (period gap), ADVB (no annual filing), BIAF (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NEO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NEO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NEOand get the insider, 13F, options, and confluence read in one view.